Country: United States
Sector: Health Care
Website: http://www.abbvie.comAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
2.70%
607.30 ARS
Oct. 15, 2024
20.27%
Year | Total Dividends |
---|---|
2025 | 291.79 ARS |
Nov. 15, 2025 (estimated) | 148.5655 |
Aug. 15, 2025 (estimated) | 143.2200 |
2024 | 418.20 ARS |
Nov. 15, 2024 | 148.5655 |
Aug. 15, 2024 | 143.2200 |
Feb. 15, 2024 | 126.4193 |
2023 | 56.54 ARS |
Aug. 15, 2023 | 24.7540 |
Feb. 15, 2023 | 31.7903 |
Yearly aggregated dividends
AbbVie Inc.
Nov 15, 2024 Paid
Dividend
148.5655 ARS |
AbbVie Inc.
Aug 15, 2024 Paid
Dividend
143.22 ARS |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion